2019 Symposium

2018 Symposium

2017 Symposium

2016 Symposium

2015 Symposium

2014 Symposium

2013 Symposium

2013 Symposium Photos

2012 Featured Talks

2012 Symposium Photos

2011 Featured Talks

2011 Symposium Photos

Past Symposia in the Press

2012 Featured Talks » PAK Inhibitors for Cancer - Trailblazing a Path to the Clinic

PAK Inhibitors for Cancer – Trailblazing a Path to the Clinic

David Campbell, PhD, Afraxis

» Download Audio

Prior to Afraxis, Dr. Campbell served as a member of the Phenomix Corporation executive team since 2003, most recently as an executive officer and senior vice president, discovery and development with responsibility for all drug discovery and development thru early clinical development to proof of concept in humans. Dr. Campbell was the senior vice president of chemical sciences at ActivX Biosciences from 2001 to 2003, where he directed the company's internal drug discovery programs as well as the development of ActivX's activity-based chemical probes. Dr. Campbell was director of discovery chemistry at Bayer Corporation where he directed the research efforts of the 41-scientist group discovering and optimizing drugs in the cancer, obesity, osteoporosis, and diabetes therapeutic areas. Dr. Campbell began his career at Affymax Research Institute, a combinatorial chemistry company that was creating novel technologies and strategies to facilitate the identification and optimization of compounds for the treatment of cancer and immune-mediated diseases.

Dr. Campbell holds three sole-authored and fifteen jointly authored patents, and has co-authored 30 original papers. He conducted post-doctoral studies at the University of California, Berkeley after receiving a Ph.D. in organic chemistry from Cornell University and a B.S. in chemistry from Harvey Mudd College.